The role of micro-RNAs in neuropathic pain-a scoping review.
Diabetic neuropathy
Gene expression
MiRNA
Neuropathic pain
RNA
Scoping review
Journal
Pain reports
ISSN: 2471-2531
Titre abrégé: Pain Rep
Pays: United States
ID NLM: 101683899
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
11
12
2022
revised:
08
09
2023
accepted:
23
09
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Neuropathic pain can be caused by a lesion or disease of the somatosensory system characterised by pathological neuro-immune alterations. At a molecular level, microRNAs (miRNAs) act as regulators of gene expression orchestrating both immune and neuronal processes. Thus, miRNAs may act as essential modulators of processes for the establishment and maintenance of neuropathic pain. The objective/aims of this scoping review was to explore and chart the literature to identify miRNAs that are dysregulated in neuropathic pain. The following databases were searched from inception to March 2023: PubMed, EBSCO, CINAHL, Cochrane Library, and SCOPUS. Two independent reviewers screened, extracted data, and independently assessed the risk of bias in included studies. The JBI critical appraisal checklist was used for critical appraisal. A narrative synthesis was used to summarise the evidence. Seven studies (total of 384 participants) that met our eligibility criteria were included in this scoping review. Our review has identified different miRNAs that are commonly involved in the chronic neuropathic pain conditions including miR-132, miR-101, and miR-199a. Our review findings further suggest that expression of miRNAs to be significantly associated with increased diabetic disease duration, HbA1C levels, and fibrinogen levels. Our review findings suggest that there is clear association between miRNA expression and chronic neuropathic pain conditions. Therefore, increasing the specificity by selecting a candidate miRNA and identifying its target mRNA is an area of future research.
Identifiants
pubmed: 37928202
doi: 10.1097/PR9.0000000000001108
pii: PAINREPORTS-D-22-0152
pmc: PMC10624461
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e1108Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
Mol Pain. 2015 Apr 12;11:19
pubmed: 25885346
Front Mol Neurosci. 2013 Oct 17;6:33
pubmed: 24151455
Trends Mol Med. 2011 Oct;17(10):548-55
pubmed: 21813326
Int J Mol Med. 2018 Jan;41(1):501-510
pubmed: 29115575
Curr Protoc Pharmacol. 2017 Dec 20;79:9.25.1-9.25.10
pubmed: 29261227
Mol Cancer. 2006 Jun 19;5:24
pubmed: 16784538
J Clin Med. 2022 Jan 26;11(3):
pubmed: 35160066
Exp Neurol. 2016 Sep;283(Pt A):276-86
pubmed: 27349406
Eur J Pain. 2013 Nov;17(10):1502-10
pubmed: 23703952
Neurosci Lett. 2020 Jun 11;729:134946
pubmed: 32278027
Curr Alzheimer Res. 2012 May;9(4):425-35
pubmed: 22191566
Lancet Neurol. 2012 Nov;11(11):999-1005
pubmed: 23079556
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Diabetes Care. 2011 Oct;34(10):2220-4
pubmed: 21852677
Adv Pharmacol. 2016;75:35-62
pubmed: 26920008
J Alzheimers Dis. 2008 May;14(1):27-41
pubmed: 18525125
Oxid Med Cell Longev. 2022 Feb 10;2022:8622388
pubmed: 35242280
Kaohsiung J Med Sci. 2019 Mar;35(3):139-145
pubmed: 30887716
Sci Rep. 2018 Jan 10;8(1):243
pubmed: 29321621
Nat Rev Neurol. 2011 Sep 13;7(10):573-83
pubmed: 21912405
Neurobiol Learn Mem. 2011 Jul;96(1):89-94
pubmed: 21524708
Mol Pain. 2012 Feb 27;8:14
pubmed: 22369085
Eur J Pain. 2006 May;10(4):287-333
pubmed: 16095934
Br J Anaesth. 2006 Oct;97(4):553-8
pubmed: 16885169
Mol Pain. 2008 Sep 15;4:35
pubmed: 18793388
Eur J Pharmacol. 2011 Jul 1;661(1-3):15-21
pubmed: 21536024
J Neuroinflammation. 2016 Sep 20;13(1):248
pubmed: 27646435
Neurosci Biobehav Rev. 2016 Jan;60:121-38
pubmed: 26593111
Pain. 2019 Jan;160(1):53-59
pubmed: 30586071
Int Immunopharmacol. 2022 Mar;104:108508
pubmed: 34999395
J Transl Med. 2011 Nov 10;9:195
pubmed: 22074333
Nat Neurosci. 2007 Dec;10(12):1513-4
pubmed: 17994015
Nat Rev Endocrinol. 2013 Sep;9(9):513-21
pubmed: 23629540
Mol Med Rep. 2017 Sep;16(3):2417-2424
pubmed: 28677735
FEBS Open Bio. 2015 Aug 31;5:733-40
pubmed: 26448907
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Int Immunopharmacol. 2017 May;46:156-162
pubmed: 28284149
Circ Res. 2020 Nov 6;127(11):1384-1400
pubmed: 32907486
Neuronal Signal. 2020 Apr;4(1):NS20190099
pubmed: 32587755
Mol Pain. 2019 Jan-Dec;15:1744806919860323
pubmed: 31218919
Biotechnol Appl Biochem. 2020 Mar;67(2):294-302
pubmed: 31737949
J Pain. 2022 Jun;23(6):967-980
pubmed: 34974173
Front Neurol. 2021 Nov 26;12:738530
pubmed: 34899562
Neurochem Res. 2021 Apr;46(4):957-963
pubmed: 33566299
Pharmacol Ther. 2017 Dec;180:1-15
pubmed: 28579386
J Cell Biochem. 2018 Jan;119(1):1017-1026
pubmed: 28685867
Pain Med. 2013 May;14(5):720-9
pubmed: 23461866
PeerJ. 2022 Jan 05;10:e12715
pubmed: 35036096
Immunol Lett. 2021 Apr;232:20-26
pubmed: 33508370
Nat Rev Dis Primers. 2017 Feb 16;3:17002
pubmed: 28205574
Heliyon. 2022 Mar 24;8(3):e09178
pubmed: 35368523
Immunol Lett. 2022 May;245:69-78
pubmed: 35398394
PLoS One. 2013;8(2):e53823
pubmed: 23405074
J Pharmacol Exp Ther. 2016 Apr;357(1):84-93
pubmed: 26787772